By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Breast cancer drug exemestane may increase fracture risk

Women taking the anti-breast cancer drug exemestane (Aromasin) should have regular bone monitoring to assess fracture risk because the treatment speeds up loss of bone density, a study suggests.

A total of 4,500 healthy post-menopausal women from families with a history of breast cancer took part in the study to determine the effectiveness of the drug.

The drug, which is an aromatase inhibitor and so reduces levels of oestrogen which some breast cancers feed off to grow, was extremely effective, cutting the risk of breast cancer by nearly two-thirds.

But a sub-study by bone specialists from Canada measured the bone density of 351 of the women, who were either on exemestane (Aromasin) or a placebo.

Those taking the drug suffered a high loss of bone density at the distal radius, a common fracture point in the wrist, as well as at the lower end of the tibia.

There was also an 8% reduction in the thickness of their bone’s protective outer shell, the cortical bone.

Lead study author Angela Cheung, of Toronto’s University Health Network, said that as well as regular bone monitoring, such patients should also have sufficient calcium and vitamin D supplements to tackle the increased fracture risk.


Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!